Literature DB >> 24879806

Life expectancy following orbital exenteration.

James Chiun Lon Wong1, Reshma Thampy2, Anne Cook2.   

Abstract

Orbital exenteration is a physically debilitating procedure that may be a necessity in the management of orbital malignancy. It requires a sensitive multidisciplinary approach, both preoperatively and postoperatively. Providing life expectancy information for patients during preoperative counselling is pertinent to informed consent and in addressing patients' expectations. A retrospective review from one tertiary care centre was undertaken for a cohort of patients who were exenterated for orbital malignancy between 1998 and 2010. The cases were identified using an International Classification of Diseases 10th Revision (ICD-10)-derived database and were analysed using Prism statistical software (V.5.04). Cause of death was ascertained by liaising with the general practitioner and the National Registrar Office for Births, Deaths, and Marriages, Southport, UK. In total, 41 men and 32 women were identified. Mean age was 72 years with 47 cases living and 26 deceased at the time of review. The overall 5-year survival rate in this study was 64%. Kaplan-Meier analysis for basal cell carcinoma (BCC) against non-BCC returned a p value of 0.0199, with an HR of 0.3927 (CI 0.1788 to 0.8626). Kaplan-Meier analysis for cleared against non-cleared margins returned a p value of 0.2890, with an HR of 0.6571(CI 0.3024 to 1.428). Our results represent the highest 5-year survival data to date. However, the overall prognosis for patients who undergo orbital exenteration for malignancy remains poor. We hypothesise that the causes are multi-factorial. We recommend a multidisciplinary approach to the care of these patients, involving head and neck teams, oncology and other appropriate specialties, to optimise outcomes for this vulnerable patient group. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Cosmesis; Neoplasia; Prosthesis; Rehabilitation; Treatment Surgery

Mesh:

Year:  2014        PMID: 24879806     DOI: 10.1136/bjophthalmol-2013-304436

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  6 in total

1.  Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival.

Authors:  R C Gerring; C T Ott; J M Curry; Z B Sargi; S T Wester
Journal:  Eye (Lond)       Date:  2016-10-21       Impact factor: 3.775

2.  Clinicopathological profile of orbital exenteration: 14 years of experience from a tertiary eye care center in South India.

Authors:  Mohammad Javed Ali; Aditi Pujari; Tarjani Vivek Dave; Swathi Kaliki; Milind N Naik
Journal:  Int Ophthalmol       Date:  2015-08-07       Impact factor: 2.031

3.  Sandwich Fascial Anterolateral Thigh Flap in Head and Neck Reconstruction: Evolution or Revolution?

Authors:  Mario Cherubino; Jens Berli; Mario Turri-Zanoni; Paolo Battaglia; Francesca Maggiulli; Martina Corno; Federico Tamborini; Edoardo Montrasio; Paolo Castelnuovo; Luigi Valdatta
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-01-17

4.  Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.

Authors:  Kai Yuen Wong; Kate Fife; John T Lear; Richard D Price; Amer J Durrani
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-07-21

5.  Clinico-Pathological Patterns of Patients Who Underwent Orbital Exenteration in a Tertiary Eye Hospital of Nepal.

Authors:  Limbu Ben; Mengesha Aemero; Anya G Gushchin; Grant H Moore; Saiju Rohit
Journal:  Ethiop J Health Sci       Date:  2016-11

6.  Factors related to survival outcomes following orbital exenteration: a retrospective, comparative, case series.

Authors:  Orapan Aryasit; Passorn Preechawai; Chakree Hirunpat; Orasa Horatanaruang; Penny Singha
Journal:  BMC Ophthalmol       Date:  2018-07-28       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.